
ERRATA

The November 20, 2014, article by Shinagawa et al, entitled “Tamibarotene As Maintenance Therapy for Acute Promyelocytic Leukemia: Results From a Randomized Controlled Trial” (J Clin Oncol 32:3729-3735, 2014), contained errors.

In the Results section, under the heading, “Patients,” the second, third, and fourth sentences of the second paragraph were given as:

“For remission induction, 133 patients (39%) were included in treatment group A, 56 (16%) in group B, 69 (20%) in group C, and 86 (25%) in group D. Group D consisted of 83 patients who had been initially treated as group A, two patients who had been treated as group B, and one patient who had been treated as group C. CR was attained in 319 (93%) of the 344 eligible patients; CR rates by group were as follows: 92% for group A, 91% for group B, 87% for group C, and 99% for group D.”

Whereas they should have been:

“For remission induction, **112 patients (33%)** were included in treatment group A, **48 (14%)** in group B, **70 (20%)** in group C, and **114 (33%)** in group D. Group D consisted of **104** patients who had been initially treated as group A and **10** patients who had been treated as group B. CR was attained in

319 (93%) of the 344 eligible patients; CR rates by group were as follows: **97%** for group A, **94%** for group B, 87% for group C, and **91%** for group D).”

The numbers of patients by induction therapy group given in Table 1 have been updated to reflect these changes.

Also, Table 2 gave the number of patients in the ATRA arm by induction therapy group as: Group A: 49; Group B: 21; Group C: 25; and Group D: 40; whereas it should have been Group A: **47**; Group B: **18**; Group C: **26**; and Group D: **44**. Table 2 also gave the number of patients in the Tamibarotene arm by induction treatment group as: Group A: 45; Group B: 22; Group C: 26; and Group D: 41; whereas it should have been Group A: **45**; Group B: **20**; Group C: **26**; and Group D: **43**.

Finally, the x-axes in Figure 2 were given as 0 to 50 in 10-year increments, whereas they should have been 0 to 5 in 1-year increments.

The online version has been corrected in departure from the print. The authors apologize for the content errors in the text.

DOI: 10.1200/JCO.2014.60.3522; published January 10, 2015

The November 20, 2014, article by Ladra et al, entitled “Preliminary Results of a Phase II Trial of Proton Radiotherapy for Pediatric Rhabdomyosarcoma” (J Clin Oncol 32: 3762-3770, 2014), contained an error. The following acknowledgement of support was inadvertently omitted: “Supported by Grant No. P01CA021239 from the

National Cancer Institute (NCI), National Institutes of Health.”

The online version has been corrected in departure from the print.

DOI: 10.1200/JCO.2014.60.3530; published January 10, 2015
